International Newsletter
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Europe will need 44 million immigrants by the year 2,050 because population growth is not keeping pace with economic development. Immigrants are needed to work in agriculture, construction, and other services to sustain the European economy. In Germany, the country with the largest contingent of immigrants, 7 million are legal whereas 1 million are illegal. On the entire continent, nearly 3 million immigrants have no legal documentation. Authorities in Spain, which serves as a European bridge for Africa and Latin America, estimate that 300,000 immigrants are without papers. Immigrants to Europe come from Africa, the Balkans, India, Turkey, and Latin America. Their health has become a central concern for sanitation authorities, particularly in Spain and some other countries where illegal immigrants are smuggled in. It is not just AIDS and tuberculosis but parasitic diseases, seldom seen by local physicians, that are introduced by the newcomers. It is now common to see onchocerciasis, a lymphatic filariasis that causes blindness, cerebral malaria that is often fatal, and neurocysticercosis—the modern great simulator.
More than 300,000 Ecuadorians have immigrated to Spain in recent years. In rural areas of Ecuador, neurocysticercosis affects 1 in 5 inhabitants. Two percent of Ecuadorians carry Taenia solium, a 3-meter tapeworm that causes neurocysticercosis. This statistic suggests that 6,000 Ecuadorians living in Spain are potential transmitters of eggs laid by the taenia in the intestine of the carrier. The eggs are generated daily in the hundreds of thousands by proglottids of T. solium and may find their way via fecal contamination …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
Dr. Kathleen Digre and Dr. Kendra Pham
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Views & Reviews
Neurocysticercosis in the United StatesReview of an important emerging infectionMitchell T. Wallin, John F. Kurtzke et al.Neurology, November 08, 2004 -
Articles
Active epilepsy as an index of burden of neurocysticercosis in Vellore district, IndiaV. Rajshekhar, M. Venkat Raghava, V. Prabhakaran et al.Neurology, December 26, 2006 -
Five New Things
NeurocysticercosisFive new thingsArturo Carpio, Agnès Fleury, W. Allen Hauser et al.Neurology: Clinical Practice, April 15, 2013 -
Resident and Fellow Section
International Issues: Educational programs of the World Federation of NeurologyT. Munsat, J. Aarli, M. Medina et al.Neurology, March 09, 2009